Strategic Partnership Boosts Cantourage Group SE Amid Legislative Shifts

Cantourage Group SE has forged a significant strategic partnership with Portocanna, aiming to scale its production capacities quickly and efficiently. The move comes in response to growing demand for medical cannabis in Germany, driven by recent regulatory changes.

As of April, cannabis is no longer classified as a narcotic in Germany, easing its prescription and dispensing procedures. This regulatory shift has markedly increased the demand for medical cannabis. Cantourage, equipped with its telemedicine platform telecan° and a network of over 60 growers, is well-positioned to capitalize on this growth.

Preliminary figures show a 26% year-over-year sales growth for Q1, totaling € 6.2 million. Following the legislative change, April sales surged by 160% compared to the previous year. Analysts predict continued high double-digit growth through the rest of the year, leading to a significant improvement in EBITDA, expected to turn positive after last year’s € 500k loss.

The partnership with Portocanna allows Cantourage to double its annual processable capacity without major investments. With production expected to rise to 14 tons annually, the potential revenue could exceed € 100 million per year. Additionally, Cantourage will exclusively distribute Portocanna's Hexacan product line, further expanding its market offerings.